4-[(2-甲基-2-丙基)氧基]苯甲酰氯 | 263841-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-[(2-甲基-2-丙基)氧基]苯甲酰氯
• 英文名称: 4-tert-butoxybenzoyl chloride
• 英文别名: 4-[(2-methylpropan-2-yl)oxy]benzoyl chloride
• CAS: 263841-86-7
• 化学式: C₁₁H₁₃ClO₂
• 分子量: 212.676
• InChiKey: MOSCUZNEJUIWHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-aminophenyl)-4-methoxybenzamide 、 4-[(2-甲基-2-丙基)氧基]苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以28%的产率得到4-methoxy-N-[2-[[4-[(2-methylpropan-2-yl)oxy]benzoyl]amino]phenyl]benzamide
  参考文献：
  名称：

  1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa

  摘要：

  High-throughput screening of a combinatorial library of diamidophenols yielded lead compounds with the ability to inhibit human factor Xa (fXa) at micromolar concentrations (e.g. compound 4, fXa apparent K-ass = 0.64 x 10(6) L/mol). SAR studies in this novel structural series of fXa inhibitors showed that the phenolic hydroxyl group was not essential for activity. The best activity was found in substituted 1,2-dibenzamidobenzenes in which the phenyl group of one benzoyl group (A-ring) was substituted in the 4-position with relatively small lipophilic or polarizable groups such as methoxy, vinyl, or chloro and the phenyl group of the other benzoyl group (B-ring) was substituted in the 4-position with larger lipophilic groups such as tert-butyl or dimethylamino. The central phenyl ring (C-ring) tolerated a wide variety of substituents, but methoxy, methanesulfonamido, hydroxyl, and carboxyl substitution produced slightly higher levels of activity than other substituents when present in combination with favorable B-ring substitution. Methylation of the amide nitrogen atoms was found to greatly decrease activity. Compound 12 is the highest affinity fXa inhibitor in this group of compounds, having fXa apparent K-ass = 25.5 x 10(6) L/mol, about 40x more active than the original lead. This lead series does not show potent inhibition of human thrombin. A model for the binding of these ligands to the fXa active site is proposed. The model is consistent with the observed SAR and can serve to guide future SAR studies.

  DOI：

  10.1021/jm990326m
• 作为产物：
  描述：

  4-叔丁氧基苯甲酸 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 生成 4-[(2-甲基-2-丙基)氧基]苯甲酰氯
  参考文献：
  名称：

  作为 P-糖蛋白抑制剂的新型苯并五元杂环衍生物：设计、合成、分子对接和抗多药耐药活性

  摘要：

  提出的克服化疗中抗癌药物多药耐药性 (MDR) 的策略是禁用 P-糖蛋白 (P-gp) 的外排功能。本研究基于环合并和片段生长策略，设计、合成和筛选了 105 种新型苯并五元杂环衍生物。对结构-活性关系 (SAR) 的探索导致了对 MCF-7/ADR 细胞中具有低细胞毒性和对多柔比星有希望的逆转活性的d7的鉴定。此外，机制研究表明，d7的逆转活性源于对 P-gp 流出的抑制。分子对接进一步阐明了观察到的 SAR 趋势，其中d7显示出对 P-gp 的强亲和力。此外，共同管理d7与多柔比星在异种移植模型中比单独使用多柔比星获得更强的抗肿瘤活性。这些结果表明d7是一种潜在的 MDR 揭示剂，可作为 P-gp 抑制剂，并为未来开发新的 P-gp 抑制剂提供指导。

  DOI：

  10.1021/acs.jmedchem.2c01999

文献信息

• [EN] INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE<br/>[FR] INHIBITEUR DE DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2011080718A1

  公开（公告）日：2011-07-07

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体形式；以及它们的药学上可接受的盐、药学上可接受的溶剂合物和药学上可接受的多晶形态。该发明还涉及制备这些杂环化合物的方法以及含有它们的药物组合物。所述化合物及其药物组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，特别是DGAT1。本发明进一步提供了一种治疗这些疾病或紊乱的方法，通过向有需要的哺乳动物施用所述化合物或其药物组合物的治疗有效量。
• [EN] PHOSPHINYL AMIDINE COMPOUNDS, METAL COMPLEXES, CATALYST SYSTEMS, AND THEIR USE TO OLIGOMERIZE OR POLYMERIZE OLEFINS<br/>[FR] COMPOSÉS DE PHOSPHINYLAMIDINE, COMPLEXES DE MÉTAL, SYSTÈMES DE CATALYSEUR, ET LEUR UTILISATION POUR OLIGOMÉRISER OU POLYMÉRISER DES OLÉFINES
  申请人：CHEVRON PHILLIPS CHEMICAL CO

  公开号：WO2011082192A1

  公开（公告）日：2011-07-07

  N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, N2-phosphinyl amidinate metal salt complexes are described. Methods for making N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N2-phosphinyl amidine metal salt complexes and N2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.

  描述了N2-膦胺化合物、N2-膦胺酸盐、N2-膦胺金属盐络合物、N2-膦胺酸盐金属盐络合物。还公开了制备N2-膦胺化合物、N2-膦胺酸盐、N2-膦胺金属盐络合物和N2-膦胺酸盐金属盐络合物的方法。还公开了利用N2-膦胺金属盐络合物和N2-膦胺酸盐金属盐络合物的催化剂系统，以及利用N2-膦胺化合物、N2-膦胺酸盐、N2-膦胺金属盐络合物和N2-膦胺酸盐金属盐络合物进行烯烃的寡聚和/或聚合的用途。
• [EN] PREPARATION OF ARYL BROMOARYL KETONES AND CARBOXYLIC DERIVATIVES THEREOF<br/>[FR] PREPARATION DE CETONES D'ARYLE BROMOARYLE ET LEURS DERIVES CARBOXYLIQUES
  申请人：ALBEMARLE CORPORATION

  公开号：WO1998037052A1

  公开（公告）日：1998-08-27

  (EN) An aroyl halide is brominated in the liquid phase with bromine and with a Lewis acid catalyst. If the reaction mixture comprises excess bromine along with m-bromoaroyl halide, substantially all of the excess bromine is removed from the mixture. The m-bromoaroyl halide mixing and reacting with a substituted or unsubstituted aromatic compound to produce a reaction mixture comprising a substituted diaryl ketone in which the substitution comprises a bromine atom in the meta position of one of its rings directly bonded to the carbonyl group. Preferably, the substituted diaryl ketone is reacted with a vinylic olefin in a palladium-catalyzed arylation of the olefin to form a substituted diaryl ketone in which the substitution comprises an olefinic substituent in the meta position of one of its rings formerly occupied by a bromine atom. This product can then be reacted with carbon monoxide in a palladium-catalyzed hydrocarboxylation or hydrocarbalkoxylation reaction. The process enables the efficient large scale production of carboxylic acids, or derivatives thereof, such as 2-(3-benzoylphenyl)propionic acid (also known as ketoprofen), a well known commercially successful anti-inflammatory and analgesic agent.(FR) On brome un halogénure d'aroyle en phase liquide avec du brome et un catalyseur à l'acide de Lewis. Si le mélange réactionnel contient trop de brome dans l'halogénure de m-bromoaryle on enlève sensiblement tout le surplus de brome du mélange. On mélange et on fait réagir l'halogénure de bromoaryle avec un composé aromatique substitué ou non substituée pour produire un mélange réactionnel comprenant une cétone de diaryle substituée dans laquelle la substitution comprend un atome de brome en position méta d'un de ses anneaux directement lié au groupe carbonyle. On fait de préférence réagir la cétone de diaryle substituée avec une oléfine vinylique dans un processus d'arylation de l'oléfine catalysé au palladium pour former une cétone de diaryle substituée dans laquelle la substitution comprend un substituant oléfinique dans la position méta d'un de ses anneaux occupée auparavant par un atome de brome. On peut ensuite faire réagir ce produit avec du monoxyde de carbone dans une réaction d'hydrocarboxylation ou d'hydrocarbalcoxylation catalysé au palladium. Ce procédé permet de produire efficacement et à grand rendement des acides carboxyliques ou des dérivés de ces derniers tels que l'acide 2-(3-benzoylphényl) acide propionique (également connu sous le nom de kétoprofène) qui est un agent analgésique et anti-inflammatoire très connu dont la vente est un succès commercial.

  一种芳酰卤化物在液相中通过溴和Lewis酸催化剂进行卤化。如果反应混合物中含有过量的溴和m-溴芳酰卤化物，则几乎所有过量的溴都会从混合物中去除。m-溴芳酰卤化物与取代或未取代的芳香化合物混合并反应，产生一种反应混合物，其中取代基在其中一个环的间位直接与羰基基团相连，并带有一个溴原子。最好的方法是将取代的二芳基酮与vinyl烯烃在钯催化的芳基化反应中反应，形成一种取代的二芳基酮，其中取代基在其中一个环的间位原来被溴原子占据，现在被烯丙基取代。然后可以将该产品与一氧化碳在钯催化的羰化或羰基醇化反应中反应。该过程使得大规模高效地生产羧酸或其衍生物成为可能，例如2-(3-苯甲酰基)丙酸（也称为左旋酮布洛芬），这是一种广泛应用的商业成功的抗炎和镇痛药物。
• INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE
  申请人：Jadhav Ravindra Dnyandev

  公开号：US20120289505A1

  公开（公告）日：2012-11-15

  The present invention relates to heterocyclic compounds in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及杂环化合物及其所有立体异构体和互变异构体；以及它们的药学上可接受的盐，药学上可接受的溶剂化合物和药学上可接受的多晶形态。本发明还涉及制造这些杂环化合物的方法以及含有它们的制药组合物。所述化合物及其制药组合物在预防和治疗由二酰基甘油酰基转移酶（DGAT）介导的疾病或紊乱方面具有用途，尤其是DGAT1。本发明还提供了一种通过向需要治疗的哺乳动物中给予所述化合物或其制药组合物的治疗方法来治疗这些疾病或紊乱的方法。
• [EN] INHIBITORS OF URAT1 AND PHARMACEUTICAL USES THEREOF<br/>[FR] INHIBITEURS D'URAT1 ET UTILISATIONS PHARMACEUTIQUES ASSOCIÉES
  申请人：NEXYS THERAPEUTICS INC

  公开号：WO2022169974A1

  公开（公告）日：2022-08-11

  The present invention relates to pharmaceutical compounds, compositions, combinations, and methods, especially as they are related to compositions and methods for the treatment and/or prevention of conditions such as gout that are associated with excessive levels of uric acid. The invention provides compounds of Formula (I) as further described herein, which inhibit activity of urate reabsorption transporter 1 (URAT1, also known as SLC22A12). The compounds are useful to treat conditions associated with excessive levels of uric acid, such as gout.

  本发明涉及制药化合物、组合物、组合以及方法，特别是涉及与含有过多尿酸相关的痛风等疾病的治疗和/或预防的组合物和方法。本发明提供了式(I)的化合物，如下文所述，该化合物抑制尿酸重吸收转运蛋白1 (URAT1，也称为SLC22A12)的活性。这些化合物可用于治疗与尿酸含量过高相关的疾病，如痛风。